Ginkgo Bioworks continues to face a weak demand environment, which has contributed to a lack of growth in recent years. Learn ...

Ginkgo Bioworks (NYSE:DNA) lost ~11% premarket Friday after the cell platform company slashed its full-year revenue outlook, citing business headwinds and effects from a newly announced restructuring ...

The average one-year price target for Ginkgo Bioworks Holdings (NYSE:DNA) has been revised to $10.88 / share. This is a ...

Ginkgo Bioworks announces the launch of Ginkgo Datapoints, which aims to make the training of AI models easier and more efficient. Ginkgo Bioworks shares are up more than 9% over the past week. Get 5 ...

Ginkgo Bioworks recently announced a five-year partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign, funded by ARPA-H, to develop new phage-based ...

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Ginkgo Bioworks announces a partnership to work with Novo Nordisk's medicines for serious chronic diseases, including diabetes and obesity. The company also announces the acquisition of AgBiome's ...